Insulin versus an oral antidiabetic agent as add-on therapy in type 2 diabetes after failure of an oral antidiabetic regimen: a meta-analysis

J.M. Gamble, Scot H. Simpson, Lauren C. Brown, Jeffrey A. Johnson

ABSTRACT

Background: Although evidence-based guidelines for the treatment of type 2 diabetes mellitus provide clear recommendations for initial therapy, evidence on an optimal treatment strategy after secondary failure is unclear.

Purpose: To compare the efficacy of add-on therapy using basal insulin versus an additional oral antidiabetic agent in patients with type 2 diabetes and secondary failure.

Data sources: We searched the following electronic databases from inception until June 2007: MEDLINE; EMBASE; Cochrane Central Register of Controlled Trials; Web of Science; Scopus; CINAHL; International Pharmaceutical Abstracts; Academic OneFile; PASCAL; Global Health Database; LILACS; HealthSTAR; PubMed. Reference lists of potentially relevant articles and clinical trial databases were searched, pharmaceutical manufacturers were contacted, and grey literature sources were sought.

Study selection: Randomized controlled trials (RCTs) involving subjects with type 2 diabetes with secondary failure who were randomly assigned to receive additional basal insulin therapy (insulin glargine, detemir, or NPH [neutral protamine Hagedorn]) versus another oral antidiabetic agent from any class.

Data extraction: Two reviewers independently screened articles, extracted data and assessed methodological quality. Our primary outcome was glycemic control measured by change in glycosylated hemoglobin (HbA\textsubscript{1C}) and the proportion of subjects achieving a HbA\textsubscript{1C} value of ≤ 7%.

Data synthesis: To compare overall efficacy between the 2 treatment strategies, change in HbA\textsubscript{1C} was pooled across studies using a random-effects model and weighted mean difference (WMD). Eleven RCTs, involving 757 participants with a median age of 56 and a median known duration of diabetes of 11 years, were included in our analysis. Insulin treatment demonstrated a small but statistically significant improvement in HbA\textsubscript{1C} compared with the use of an additional oral agent as add-on therapy (WMD -0.17; 95% CI [confidence interval] -0.33 to -0.02).

Limitations: The use of surrogate outcomes and the short duration of the trials makes it impossible to gain information on long-term patient-oriented outcomes. The overall quality of the studies was low, primarily in view of inadequate blinding.

Conclusions: Although add-on therapy using injected insulin shows a slight benefit over an additional oral antidiabetic agent, our results indicate that basal insulin therapy and the use of an oral agent as add-on therapy produce comparable results. Non-therapeutic differences must be considered in the choice of treatment strategies. More high-quality studies with adequate safety data using more aggressive insulin titrations are needed.
LOWERING BLOOD GLUCOSE WAS SHOWN TO decrease the risk of microvascular complications in the United Kingdom Prospective Diabetes Study (UKPDS) trial.\textsuperscript{1} In this study, patients randomly assigned to the intensive protocol (target fasting plasma glucose (FPG) < 6 mmol/L) showed a significant reduction in microvascular complications and a trend toward reduced macrovascular complications.\textsuperscript{1} Mainly on the basis of evidence from the UKPDS and other major diabetes clinical trials,\textsuperscript{2,3} several organizations have formulated guidelines with clear recommendations for the initial therapy of type 2 diabetes.\textsuperscript{4–6} However, in view of the progressive nature of type 2 diabetes,\textsuperscript{7} patients and their clinicians will inevitably need to intensify therapy to maintain glycemic control. The decision to intensify therapy after initial treatment with oral medication has been defined as “secondary failure.”\textsuperscript{8–10} Although clinical trial evidence conveys the importance of early and sustained blood glucose control,\textsuperscript{12,21} the optimal strategy for patients in whom initial oral antidiabetic drug therapy has proven ineffective is not well defined.

Current clinical practice guidelines\textsuperscript{4–6} for type 2 diabetes recommend the addition of either insulin or another oral agent when monotherapy using an oral agent achieves inadequate control (HbA\textsubscript{1C} > 7%). However, it unclear which of these options is preferable.

A randomized controlled trial (RCT) assessing the efficacy of intensive glycemic control (HbA\textsubscript{1C} < 6%) through an extensive protocol involving titration and the addition of various antidiabetic strategies, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial (www.accordtrial.org) is currently under way; the results, however, are not expected until at least 2010. Previous systematic reviews have not explored whether it is preferable to add insulin therapy or to add an additional oral agent in patients with secondary failure. Goudswaard et al\textsuperscript{12} focused on switching a patient’s therapeutic regimen to insulin monotherapy versus adding insulin to oral antidiabetic agents. Reviews assessing combination therapy of insulin and oral antidiabetic agents have been limited to a specific class of oral antidiabetic agents, most commonly sulfonylureas,\textsuperscript{13–15} and assessed whether combination therapy with insulin was beneficial compared with insulin monotherapy. Moreover, these previous reviews predate the launch of the newer long-acting insulins — insulin glargine and detemir.

The objective of this meta-analysis was to evaluate the evidence of the efficacy of adding basal intermediate or long-acting insulin versus the addition of another oral antidiabetic agent in patients with type 2 diabetes whose current oral antidiabetic therapy was failing.

Methods

Search strategy. The search strategy was designed to capture the patient population, consisting of people with type 2 diabetes currently using any class of oral antidiabetic therapy; the population problem, defined as current treatment failure; the intervention of insulin glargine, detemir or NPH (neutral protamine Hagedorn); and the primary outcome measure of change in glycated hemoglobin (HbA\textsubscript{1C}). Our search strategy was developed in consultation with a research librarian well versed in the conduct of systematic reviews and in the use of MeSH (MEDLINE subject headings) and key terms.

The MEDLINE-based search strategy formed the foundation for searching in other databases. We searched the following electronic bibliographic databases from their inception until June 2007: MEDLINE, EMBASE, Cochrane Register of Controlled Trials, Web of Science, Scopus, CINAHL, International Pharmaceutical Abstracts, Academic OneFile, PASCAL, Global Health Database, LILACS, HealthSTAR, and PubMed. Other literature sources were also searched, including: reference lists of all included studies and relevant narrative reviews; clinical trials databases (ClinicalTrials.gov, Cen-
terWatch Clinical Trials Listing Service, and Current Controlled Trials); OCLC Proceedings First and OCLC Papers First databases to identify studies presented at conferences and proceedings; and Proquest and Index to Theses to identify relevant theses and dissertations. We contacted the pharmaceutical companies producing insulin glargine (Sanofi-Aventis), insulin detemir (Novo Nordisk) and NPH (Novo Nordisk, Lilly) to inquire about other published or unpublished studies.

Selection of studies. Citations identified in the literature search were independently screened by two reviewers (JG, SS) to select potentially relevant articles. The full articles from this list were retrieved and subsequently reviewed by 2 reviewers (JG, LB) for inclusion in the systematic review. Inter-rater agreement at this stage was assessed using Cohen’s kappa statistic. Disagreements between reviewers were reconciled by consensus; a third-party intermediary was not required. Reviewers were not blinded to the authors, journal, or publisher of the studies. Non-English abstracts and articles were assessed by one reviewer (SK).

Studies were included if they had the following characteristics: RCTs, whether parallel or crossover design; participants inadequately controlled on their current oral antidiabetic regimen, defined as an HbA1c  > 7% or a fasting plasma glucose (FPG) > 7 mmol/L; participants insulin naive at baseline; subjects randomly assigned to receive the addition of either basal insulin therapy (insulin glargine, detemir, or NPH) or another oral antidiabetic agent from any class (biguanide, sulfonylurea, thiazolidinedione, non-sulfonylurea secretagogue, or glucosidase inhibitor). We use the term “basal” to mean administration of an intermediate or long-acting insulin as 100% of daily insulin dose; specifically, these would be regimens using NPH, glargine, or detemir.4 We felt that crossover trials were suitable for our clinical question, as diabetes management is a chronic condition of which we do not expect a carry-over effect of treatment in respect to blood glucose levels. Data from crossover trials were entered as a parallel study.

In addition to the above criteria, studies must have reported (or given the information to calculate) change in HbA1c (%) from baseline. Glycemic control was our primary outcome, measured by change in HbA1c and the proportion of individuals achieving an HbA1c ≤ 7%. Secondary outcomes included change in FPG (mmol/L), change in weight (kg) and the proportion of participants who experienced ≥ 1 hypoglycemic event as defined by the study investigators.

Data extraction and management. Two reviewers (JG, LB) independently extracted the data from all articles that met predefined eligibility criteria. Data were recorded on a standardized form, and all discrepancies were resolved by consensus. Both reviewers independently extracted data from 2 studies using a preliminary data extraction form. Minor revisions to the extraction form were made after this trial period to provide the content found in Textbox 1. We attempted to contact authors to verify, interpret and obtain missing data. In addition to extracting data, the reviewers assessed the overall methodological quality of studies using the Jadad scale.16 Methodological quality was assessed on the basis of information reported in the published article only. In addition, the scale devised by Schulz and colleagues17 was used to assess allocation of concealment. Funding sources for included studies were also considered.

If the mean change and its respective standard deviation were missing, we calculated the mean change from baseline by subtracting the mean baseline HbA1c from the mean HbA1c at the last follow-up date. Standard deviation (SD) was calculated using standard formulas,18 using a correlation coefficient of 0.5 to allow estimation of the combined SDs. In one study19 we had to estimate the values of HbA1c and fasting plasma glucose from inspection of graphs, as the exact values were not included in the publication. We substituted the mean SD from the other studies that used an identical comparison agent.

Data synthesis. We chose a random-effects model for our meta-analysis, as this is more conservative than a fixed-effects model and therefore less likely to overestimate treatment effects.20 Statistical, clinical, and methodological heterogeneity were assessed to determine the appropriateness of pooling data across studies. We evaluated statistical heterogeneity using the I2 statistic. A value of I2 greater than 50% was considered indicative of significant heterogeneity.18 We recognized the potential for variability in key clinical characteristics such as duration of diabetes, baseline HbA1c, and age; however, we used the method described by Tobias21 to explore the impact of each study on the overall summary effect.

We further explored sources of potential heterogeneity through subgroup and sensitivity analyses. Subgroups defined a priori included stratification by the type of insulin
(NPH, glargine, detemir) and the comparative oral agent (metformin, thiazolidinedione, acarbose). Sensitivity analyses were performed on the following factors, defined a priori: fixed-effects versus random-effects model; parallel versus crossover design; and duration of follow-up.

All continuous variables (changes in HbA1c, FPG, and weight) were expressed using a weighted mean difference (WMD) and 95% confidence interval (CI). All dichotomous outcomes (proportion of subjects achieving HbA1c ≤ 7%, and proportion of subjects experiencing ≥ 1 hypoglycemic event) were expressed using relative risk (RR) and 95% CI. We chose RR as a measure of effect, given considerations of consistency and interpretability. Publication bias was assessed by examining the symmetry of a funnel plot, where sample size is plotted against the treatment effect. A funnel plot was inspected for our primary outcome only, in view of the small number of studies that addressed our secondary outcomes.

Results

Search strategy. Our search strategy identified 1234 unique citations, and an additional 26 citations were identified from grey literature sources (Fig. 1). Screening of title, abstracts, and keywords identified 54 citations potentially relevant to the review question, and the full text for these studies was retrieved. Seven non-English articles were assessed by 1 reviewer (SK), who found that none met the eligibility criteria. Two reviewers assessed the remaining 47 potentially relevant articles and found that 12 studies met the eligibility criteria independently (kappa = 0.74). The reviewers arrived at a consensus that 11 studies met all of the eligibility criteria.

Included studies. Seven studies used a parallel design; 4 studies used a crossover design. Crossover studies tended to have smaller sample sizes, contributing 119 to a total of 757 participants. Trial duration ranged from 12 weeks to 1 year of follow-up. Sample sizes ranged from 12 to 219 participants. Three studies used insulin glargine, 7 studies used NPH insulin, and 1 study did not specify the type of insulin. Five studies used a thiazolidinedione (n = 1 for pioglitazone and n = 4 for rosiglitazone), 7 studies used metformin, and 1 study used acarbose as comparison agents. Baseline HbA1c ranged from 8.8% to 11.2%.

The overall quality of the studies was low (Jadad range 0–2), and only 1 study adequately described the allocation concealment method. One study was described as double-blinded; this was misleading, as the insulin arm was not blinded, and only the acarbose arm was masked with a placebo. Three studies explicitly stated that they were “open label” studies. The average percentage of dropouts per study was 13% of the number of subjects randomly assigned to a study arm. Reasons for dropouts were given in all studies, except the 2 that had no dropouts. Although 2 studies described an intention-to-treat analysis, in fact no study performed an intention-to-treat analysis.

Six studies were sponsored by a pharmaceutical company. Baseline clinical and demographic data for each study are listed in Table 1. Most studies did not explicitly state their primary outcome. In the study by Rosenstock and colleagues the primary outcome was identical to that of our systematic review: glycemic control measured using HbA1c.
Outcomes. To compare the overall efficacy of the two treatment options — addition of basal insulin versus another oral antidiabetic agent — outcome results from each study were pooled and an overall summary measure of effect was calculated. When all studies were pooled, the addition of basal insulin demonstrated a statistically significant improvement in HbA\textsubscript{1C} in comparison with the use of an oral agent as add-on therapy, but this difference was not clinically significant (WMD 0.17; 95% CI -0.33 to -0.02) (see Appendix 1 for Forest plots of meta-analyses). The pooled analyses of patients achieving HbA\textsubscript{1C} ≤ 7% favoured the addition of insulin; however, this finding did not reach statistical significance (RR 1.10; 95% CI 0.80–1.52). A third measure of glycemic control was change in FPG from baseline, where an improvement in the insulin arm versus the oral agent arm was found (WMD -1.29; 95% CI -1.61 to -0.98). With respect to adverse events, more patients experienced at least one hypoglycemic event in the insulin group than in the oral agent group (RR 1.42; 95% CI 1.11–1.80). Weight gain was not pooled into an overall meta-analysis in view of the significant heterogeneity among studies.

Results were categorized into clinically meaningful subgroups according to the type of insulin used. Eight studies compared a once-daily injection of NPH versus an oral antidiabetic as add-on therapy.\textsuperscript{19,22–25,29–31} Two of these studies used a thiazolidinedione,\textsuperscript{29,30} 5 studies used metformin\textsuperscript{19,23–25,31} and 1 study used acarbose\textsuperscript{22} as a comparator. No differences between groups were demonstrated for overall glycemic control as measured by change in HbA\textsubscript{1C} or proportion achieving an HbA\textsubscript{1C} ≤ 7%.

A greater change in FPG was observed in the NPH group than in the oral therapy group (WMD -1.64; 95% CI 2.05 to -1.22). The proportion of participants who experienced a hypoglycemic event was higher in the NPH treatment group (RR 1.89; 95% CI 1.16–3.10), as was the change in weight in kilograms from baseline (WMD 1.19; 95% CI 0.61–1.76). As expected, when NPH was compared with metformin only, even more weight gain was seen in the NPH group (WMD 1.29; 95% CI 0.62–1.96).

Three studies compared the addition of insulin glargine to an oral agent.\textsuperscript{26–28} Rosiglitazone was the only oral agent used in all 3 studies. Glycemic control did not differ significantly between groups, although the point estimates favour the addition of insulin glargine for both change in HbA\textsubscript{1C} (WMD -0.13; 95% CI -0.31 to 0.06) and the proportion of subjects achieving a target HbA\textsubscript{1C} ≤ 7% (RR 1.22; 95% CI 0.76–2.76). A significant difference was seen in favour of insulin for change in FPG (WMD 1.03; 95% CI -1.09 to -0.97) as well as weight gain (WMD -1.30; 95% CI -1.41 to -1.19). No difference was demonstrated between groups with respect to hypoglycemia (RR 1.29; 95% CI 0.98–1.71).

Sensitivity analyses, using a fixed-effects model, stratification by study design, or stratification by study duration, did not result in a substantial change in the

| Textbox 1: Data extraction |
|---------------------------|
| **General**               |
| • study identifier        |
| • name of reviewer        |
| • date of extraction      |
| • bibliographic source    |
| **Study method**          |
| • design                  |
| • method of randomization |
| • length of study         |
| • number lost to follow up|
| • number of withdrawals/dropouts|
| • reasons for withdrawal  |
| • inclusion/exclusion criteria |
| • setting and location    |
| • funding source          |
| **Population**            |
| • sample size             |
| • age and gender          |
| • current oral antidiabetic regimen |
| • baseline HbA\textsubscript{1C} (%) |
| • baseline body mass index (kg/m2) and/or weight (kg) |
| • baseline fasting plasma glucose (mmol/L) |
| • diabetes duration at baseline |
| **Intervention**          |
| • type of insulin         |
| • dose                    |
| • time of daily injection |
| • duration of therapy     |
| **Comparison**            |
| • type of oral antidiabetic agent |
| • dose, frequency         |
| • duration of therapy     |
| **Outcomes**              |
| • primary outcomes stated |
| • change or follow up HbA\textsubscript{1C} |
| • change or follow up fasting glucose |
| • definition and number of hypoglycemic episodes |
| • change or follow-up weight |
| **Analysis**              |
| • intention-to-treat or per protocol |
| • how authors dealt with missing data |
magnitude or direction of the summary effect. To test the robustness of our summary measure of effect for change in HbA1c, we used the method developed by Tobias,21 by which each study is omitted and the summary effect measure is compared with the original result. The WMD did not change by more than 10%, with the exception that when the study by Rosenstock and colleagues37 was omitted the WMD changed by 28% in favour of insulin treatment. The possibility of publication bias was suggested by asymmetry in the funnel plot.

Discussion

Management of type 2 diabetes mellitus is multifaceted, incorporating blood glucose, blood pressure, lipid, and weight control. Although guidelines recommend tight glucose control to reduce the risk of microvascular complications,4–6 many patients remain above recommended glycemic targets.32 The progressive nature of type 2 diabetes further exacerbates the difficulty in achieving and maintaining glycemic control.33 The objective of this review was to evaluate the efficacy of 2 different treatment strategies in people with type 2 diabetes in whom initial oral antidiabetic therapy had failed. We compared the addition of a basal insulin injection with the addition of another oral antidiabetic agent.

The results of this systematic review indicate that, when used as add-on therapy, basal insulin therapy and an oral agent achieve comparable glycemic control. Although insulin showed a statistically significant benefit, the difference was small and of limited clinical importance. The clinical impact of a 0.17% reduction in HbA1c associated with insulin therapy versus the addition of oral therapy must be viewed in light of the absence of large-scale quality trials. The 95% CI showed potential benefit ranging from a 0.02% to a 0.33% reduction in HbA1c. We reported pooled estimates of the WMD in change in HbA1c from baseline, comparing insulin and oral agent treatment according to the type of insulin agent used. Although the overall pooled estimate favoured the addition of basal insulin, analysis stratified

### Table 1: Study characteristics

| Study (year), type | N* | Insulin type | Oral agent | Diabetes duration (yrs) | HbA1c (%) | Age (yrs) | % M/F | BMI | OAD | Jadad score | Funding source |
|-------------------|----|--------------|------------|------------------------|-----------|-----------|-------|-----|-----|-------------|----------------|
| Aljabri39 (2004), P | 62/58 | NPH | Pioglitazone | 10 | 9.9 | 58 | 60/40 | 25.5 | Met + SU or Met + nateglinide | 2 | Eli Lilly‡ |
| Bastyr31 (2000), P | 135/114 | NPH | Metformin | 8 | 10.2 | 57 | 60/40 | 28.4 | Glyburide | 1 | Eli Lilly |
| Klein19 (1991) | 50/35 | NR | Metformin | 12 | NR | 67 | 24/76 | NR | Glibenclamide | 1 | Unclear |
| Ko30† (2006), P | 112/104 | NPH | Rosiglitazone | 13 | 9.9 | 58 | 56/44 | 24.9 | SU or Met + SU | 1 | Internal |
| López-Alverenga22 (1999), C | 37/29 | NPH | Acarbose | 10 | 11.2 | 53 | 28/72 | 27.3 | Chloropropamide + Met | 1 | Bayer |
| Reynolds26† (2007), P | 40/35 | Glargine | Rosiglitazone | 11 | 9.0 | 61 | 100/0 | 31.6 | Met + SU | 1 | GSK† |
| Rosenstock27 (2006), P | 219/216 | Glargine | Rosiglitazone | 8 | 8.8 | 56 | 52/48 | 34.1 | Met +SU | 1 | Aventis |
| Triplitt28† (2006), P | 20/20 | Glargine | Rosiglitazone | 8 | 9.3 | 48 | 40/60 | 30.2 | Met +SU | 0 | Aventis |
| Trischitta23 (1992), C | 20/16 | NPH | Metformin | 12 | 10.2 | 43 | 35/65 | NR | Glyburide | 1 | Unclear |
| Trischitta24 (1998), C | 50/45 | NPH | Metformin | 13 | 9.1 | 56 | 24/76 | 27.8 | Glibenclamide | 1 | Unclear |
| Vingeri25 (1991), C | 12/12 | NPH | Metformin | 12 | NR | 52 | NR | NR | Glyburide | 1 | Unclear |

* randomized / analyzed; M/F = male/female; BMI = body mass index (kg/m²); OAD = oral antidiabetic therapy; P = parallel design; C = crossover design; NPH = neutral protamine Hagedorn; Met = metformin; SU = sulfonylurea; NR = not reported; GSK = GlaxoSmithKline.

The study did not report the type of insulin (Klein19) was analysed with the NPH studies.

† Sponsor had no role in study design, analysis, or involvement in manuscript preparation. ‡ Additional information was obtained from the authors.
by insulin type to obtain an indirect comparison showed no apparent difference between NPH or glargine in comparison with the addition of an oral antidiabetic agent. Another outcome of interest with respect to glycemic control was the number of patients in each treatment group who achieved the target HbA$_{1C}$ ≤ 7%. The small number of patients who achieved an optimal HbA$_{1C}$ was likely related to the conservative dosing of insulin. A much larger magnitude of effect was observed with respect to change in FPG, but this might be expected insofar as insulin dosing was titrated on the basis of FPG levels in all of the studies. In view of the significant heterogeneity between NPH and glargine groups, the magnitude of effect must be considered in context. Insulin glargine was generally used as a third-line agent, whereas NPH was added as a second-line agent. Therefore, the magnitude of effect may have been influenced by other factors, such as differences in postprandial blood glucose control, which could account for the diminished effect observed in the change in HbA$_{1C}$.

The relative safety of the 2 treatment strategies was evaluated using 2 secondary outcomes: proportion of subjects experiencing ≥ 1 hypoglycemic event, and change in weight. As expected, hypoglycemic events were more frequent in the insulin group than in the oral agent group. This appears to have been driven mostly by the large number of studies that used metformin as the comparison agent. The magnitude of effect is diminished and is statistically non-significant when only studies using a thiazolidinedione are considered. Overall, there was no difference in weight gain when insulin versus an oral agent was used as add-on therapy. The significant heterogeneity observed (I$^2$ 92.8%; p < 0.001) is explained in part by subgroup analysis. Of the 7 studies that used NPH and reported weight as an outcome measure, 4 used metformin as the comparison oral agent and showed a non-significant increase in weight gain among the the NPH users (WMD 1.29; 95% CI 0.62–1.96). This is consistent with metformin use in general, which is advocated for overweight patients. In the insulin glargine subgroup, insulin users experienced significantly less weight gain than those who used rosiglitazone as an add-on agent (WMD -1.30; 95% CI -1.41 to -1.19).

Limitations. Several limitations should be considered in the interpretation of our results. First, the overall quality of the studies included in the meta-analysis was poor, as indicated by their average Jadad score. We identified several recurring problems of methodology. For example, although all studies used random allocation, the process of randomization and concealment was not adequately described. Moreover, the lack of blinding was an important limitation across all studies. Proper blinding would require a double-dummy design whereby participants would administer an injection and an oral tablet concurrently. Second, follow-up times were relatively short, considering that people with type 2 diabetes receive treatment for the rest of their lives. Two studies had a follow-up of 1 year. However, the 2 treatment groups might not show comparable efficacy after 2, 5, or 10 years. Longer follow-up times would increase the external validity of the results. A third limitation is that our primary outcomes are surrogate markers and lack information on long-term outcomes, such as microvascular or cardiovascular events. A fourth consideration concerns the limit to which a triple oral therapy can lower HbA$_{1C}$. The addition of a third oral agent is unlikely to decrease HbA$_{1C}$ levels by greater than 1.5% to 2.0%; therefore, insulin may be a more appropriate option for those whose diabetes is very poorly controlled (> 9.5%) with secondary oral antidiabetic therapy. Evidence for this exists in the findings of Rosenstock and colleagues, which show that the glucose-lowering benefit of insulin glargine, as measured by FPG, was greater when baseline HbA$_{1C}$ was ≥ 9.5%. A fifth limitation is the absence of data for secondary outcomes. Hypoglycemic event reporting was inconsistent, and definitions of hypoglycemia were rare (n = 3). Similarly, reporting on weight change was inconsistent between studies. Consistent reporting of other side-effects such as edema or pain at the injection site would aid in the applicability of the results.

Although every effort was made to minimize biases in the review process, potential biases still exist. These biases were limited the involvement of 2 independent reviewers involved at each major stage in the review process. Publication bias was suggested by asymmetry observed on the funnel plot, although other sources of bias, including selection bias, true heterogeneity, data irregularities, artifact, or chance may explain this asymmetry.

The results of this systematic review are relevant for clinicians working with patients with poorly controlled type 2 diabetes who are using either a sulfonylurea as monotherapy or in combination with metformin. The choice of treatment regimens for add-on therapy should be evaluated in light of current HbA$_{1C}$ levels and the risk of hypoglycemia. Non-therapeutic reasons such as cost...
and patient preference or adverse effects should be given adequate weight in view of the small magnitude of benefit observed for insulin use as add-on therapy. The optimal strategy for adding basal insulin therapy to an oral antidiabetic regimen remains to be demonstrated. More rigorous studies are required to establish the ideal treatment strategy for people with type 2 diabetes experiencing secondary failure on oral antidiabetic therapy.

Acknowledgments: The authors thank Tamara Durec for assistance designing and implementing the search strategy; Stefan Kuhle for evaluating all non-English articles; Donna Dryden for providing comments on an early draft; and Drs Raymond Reynolds, Curtis Triplitt, and Gary Ko for providing additional data from their respective studies.

REFERENCES

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837–53. [PubMed]

2. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28(2):103–17. [PubMed]

3. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care 1995;18(8):1113–23. [PubMed]

4. Canadian Diabetes Association. 2003 Clinical Practice Guidelines. Can J Diabetes 2003;S1–S82.

5. American Diabetes Association. Standards of medical care in diabetes—2007. Diabetes Care 2007;30 Suppl 1(Suppl 1):S4–S84. [CrossRef] [PubMed] [Full Text]

6. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer M, et al. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC), European Association for the Study of Diabetes (EASD), Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28(1):88–136. [CrossRef] [PubMed] [Full Text]

7. U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995;44(11):1249–58. [PubMed]

8. Ehrich DT, Simpson SH, Majumdar SR, Johnson JA. Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus. Pharmacotherapy 2005;25(6):810–6. [PubMed]

9. Nichols GA, Alexander CM, Girman CJ, Kamal-Bahl SJ, Brown JB. Contemporary analysis of secondary failure of successful sulfonylurea therapy. Endocr Pract 2007;13(1):37–44. [PubMed]

10. Groop LC, Pelkonen R, Koskimies S, Bottazzo GF, Doniach D. Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care 1986;9(2):129–33. [PubMed]

11. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329(14):977–86. [PubMed] [Full Text]

12. Goudswaard AN, Furlong NJ, Rutten GEHM, Stolk RP, Valk GD. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2004;4(4):CD003418. [CrossRef] [PubMed]

13. Johnson JL, Wolf SL, Kahadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Arch Intern Med 1996;156(3):259–64. [PubMed]

14. Peters AL, Davidson MB. Insulin plus a sulfonylurea agent for treating type 2 diabetes. Ann Intern Med 1991;115(1):45–53. [PubMed]

15. Pugh JA, Wagner ML, Sawyer J, Ramirez G, Tuley M, Friedman SJ. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. Diabetes Care 1992;15(8):953–9. [PubMed]

16. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17(1):1–12. [PubMed]

17. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408–12. [PubMed]

18. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. 4.2.6. Chichester (UK): John Wiley & Sons; 2006.

19. Klein W. Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in secondary failures of sulfonylurea monotherapy. Results of a prospective randomized study in 50 patients. Diabete Metab 1991;17(1 Pt 2):235–40. [PubMed]

20. Scott I, Greenberg P, Poole P, Campbell D. Cautionary tales in the interpretation of systematic reviews of therapy trials. Intern Med J 2006;36(9):587–99. [CrossRef] [PubMed]

21. Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Technical Bulletin 1999:15–17.

22. López-Alvarenga JC, Aguilar-Salinas CA, Velasco-Perez ML, Arita-Melzer O, Guellen LE, Wong B, et al. Acarbose vs. bedtime NPH insulin in the treatment of secondary failures to sulphonylurea-metformin therapy in type 2 diabetes mellitus. Diabetes Obes Metab 1999;1(1):29–35. [PubMed]

23. Trischitta V, Italia S, Mazzarino S, Buscema M, Rabuazzo AM, Sangiorgio L, et al. Comparison of combined therapies in treatment of secondary failure to glyburide. Diabetes Care 1992;15(4):339–42. [PubMed]

24. Trischitta V, Italia S, Raimondo M, Guardabasso V, Liciardiello C, Runello F, et al. Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylures. Is it predictable? J Endocrinol Invest 1998;21(11):744–7. [PubMed]

25. Vigneri R, Trischitta V, Italia S, Mazzarino S, Rabuazzo MA, Squatrito S. Treatment of NIDDM patients with secondary failure to glyburide: comparison of the addition of either metformin or bed-time NPH insulin to glyburide. Diabete Metab 1991;17(1 Pt 2):232–4. [PubMed]
26. Reynolds LR, Kingsley FJ, Karounos DG, Tannock LR. Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes. *Diabetes Res Clin Pract* 2007;77(2):180–7. [CrossRef] [PubMed]

27. Rosenstock J, Sugimoto D, Strange F, Stewart JA, Soltes-Rak E, Davis G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. *Diabetes Care* 2006;29(3):559–64. [PubMed] [Full Text]

28. Triplitt C, Glass I, Miyazaki Y, Wajcberg E, Gastaldelli A, De Filippis E, et al. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea. *Diabetes Care* 2006;29(11):2371–7. [CrossRef] [PubMed] [Full Text]

29. Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. *Am J Med* 2004;116(4):230–5. [CrossRef]

30. Ko GTC, Tsang PCC, Wai HPS, Kan ECY, Chan HCK. Rosiglitazone versus bedtime insulin in the treatment of patients with conventional oral antidiabetic drug failure: a 1-year randomized clinical trial. *Adv Ther* 2006;23(5):799–808. [PubMed]

31. Bastyr EJ, Stuart CA, Brodows RG, Schwartz S, Graf CJ, Zagar A, et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. *Diabetes Care* 2000;23(9):1236–41. [PubMed] [Full Text]

32. Harris SB, Ekoé J, Zdanowicz Y, Webster-Bogaert S. Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). *Diabetes Res Clin Pract* 2005;70(1):90–7. [CrossRef] [PubMed]

33. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. *JAMA* 1999;281(21):2005–12. [PubMed] [Full Text]

34. Song F, Alman DG, Glenny A, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. *BMJ* 2003;326(7387):472. [CrossRef] [PubMed] [Full Text]

35. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. *BMJ* 2001;323(7304):101–5. [PubMed] [Full Text]
Appendix 1: Forest plots

Forest plot 1: Change in HbA₁C (%)

| Study ID   | RR (95% CI) | Events, insulin | Events, oral agent |
|------------|-------------|-----------------|--------------------|
| NPH        |             |                 |                    |
| Bastyr 2000| 1.62 (0.42, 6.31) | 5/38             | 3/37               |
| Algeri 2004| 0.02 (0.35, 2.40)  | 8/29             | 7/30               |
| Ko 2006    | 1.85 (0.59, 5.77)  | 8/54             | 4/50               |
| Subtotal (I² = 0.0%, p = 0.611) | 1.31 (0.69, 2.50)  | 19/120           | 14/117             |

Heterogeneity between groups: p = 0.434
Overall (I² = 7.9%, p = 0.366) 1.10 (0.80, 1.52) 79/252 74/256

Forest plot 2: Proportion of study participants achieving target HbA₁C

| Study ID   | RR (95% CI) | Events, insulin | Events, oral agent |
|------------|-------------|-----------------|--------------------|
| NPH        |             |                 |                    |
| Bastyr 2000|             |                 |                    |
| Algeri 2004|             |                 |                    |
| Ko 2006    |             |                 |                    |
| Subtotal (I² = 0.0%, p = 0.611) |             |                 |                    |

Heterogeneity between groups: p = 0.434
Overall (I² = 7.9%, p = 0.366) 1.10 (0.80, 1.52) 79/252 74/256
### Forest plot 3: Change in fasting plasma glucose (mmol/L)

| Study ID      | N, mean (SD), insulin | N, mean (SD), oral agent |
|---------------|-----------------------|--------------------------|
| NPH           |                       |                          |
| Klein 1981    | -1.70 (-3.12, -0.27)  | 19, -2.2 (2.5)           |
| Vingier 1981  | -1.70 (-2.22, -1.18)  | 12, -5.1 (8)             |
| Trischitta 1982 | -0.00 (-2.02, 1.02)  | 16, -4.8 (2.62)          |
| Trischitta 1988 | -2.20 (-3.31, -1.08) | 45, -5.3 (2.68)          |
| Lopez 1999    | -2.04 (-0.03, 0.35)   | 12, -4.8 (4.48)          |
| Basaiy 2000   | -1.20 (-2.41, 0.01)   | 36, -5.4 (2.4)           |
| Algen 2004    | -1.40 (-2.65, 0.00)   | 25, -4.3 (2.3)           |
| Ko 2008       | -1.30 (-3.01, 0.41)   | 54, -3.7 (5.3)           |
| Subtotal (I-squared = 0.8%, p = 0.870) | -1.64 (-2.06, -1.22) | 224, 223 |

**glargine**

| Study ID      | N, mean (SD), insulin | N, mean (SD), oral agent |
|---------------|-----------------------|--------------------------|
| Rosenvold 2008 | -1.03 (-1.09, -0.97)  | 104, -3.6 (2.3)          |
| Tripit 2006   | -0.60 (-2.52, 1.32)   | 10, -4.1 (2.26)          |
| Subtotal (I-squared = 0.8%, p = 0.861) | -1.03 (-1.09, -0.97) | 114, 122 |

**Heterogeneity between groups: p = 0.005**

**Overall (I-squared = 20.5%, p = 0.255)**: -1.29 (-1.61, -0.98) 308 345

**NOTE:** Weights are from random effects analysis.

### Forest plot 4: Proportion of study participants who experienced one or more hypoglycemic events

| Study ID      | RR (95% CI) | Events, insulin | Events, oral agent |
|---------------|-------------|-----------------|--------------------|
| NPH           |             |                 |                    |
| Klein 1981    | 1.66 (0.17, 16.81) | 2/19 | 1/16               |
| Lopez 1999    | 1.33 (0.21, 8.41)  | 2/15 | 2/20               |
| Algen 2004    | 1.65 (1.08, 3.16)  | 10/28 | 11/30             |
| Ko 2006       | 10.20 (0.58, 179.88) | 5/54 | 0/50               |
| Trischitta 1982 | ...        | 5/16 | 6/16               |
| Trischitta 1988 | ...        | 0/45 | 0/45               |
| Subtotal (I-squared = 0.0%, p = 0.864) | 1.99 (1.16, 3.41) | 29/177 | 14/177             |

**glargine**

| Study ID      | RR (95% CI) | Events, insulin | Events, oral agent |
|---------------|-------------|-----------------|--------------------|
| Rosenvold 2008 | 1.31 (0.96, 1.73) | 57/194 | 47/112             |
| Tripit 2006   | 0.32 (0.02, 7.32)  | 9/10 | 1/10               |
| Subtotal (I-squared = 0.0%, p = 0.896) | 1.29 (0.99, 1.71) | 51/1114 | 48/1222 |

**Heterogeneity between groups: p = 0.108**

**Overall (I-squared = 0.0%, p = 0.545)**: 1.42 (1.11, 1.90) 85/291 63/289

**NOTE:** Weights are from random effects analysis.
Appendix 2: MEDLINE final search strategy

1. Drug Therapy, Combination/
2. exp Hypoglycemic Agents/
3. exp Sulfonylurea Compounds/
4. exp Biguanides/
5. exp Glucosidases/
6. Thiazolidinediones/
7. sulfonylurea$.mp.
8. sulphonylurea$.mp.
9. biguanide$.mp.
10. (thiazolidinedione$ or TZD?).mp.
11. glitazone$.mp.
12. secretagogue$.mp.
13. glimepiride.mp.
14. amaryl.mp.
15. gliclazide.mp.
16. diamicron.mp.
17. glyburide.mp.
18. glibenclamide.mp.
19. diabeta.mp.
20. metformin.mp.
21. glucophage.mp.
22. acarbose.mp.
23. alpha glucosidase inhibitor?.mp.
24. pioglitazone.mp.
25. Actos.mp.
26. rosiglitazone.mp.
27. Avandia.mp.
28. tolbutamide.mp.
29. chloropropamide.mp.
30. 93479-97-1.m.
31. 111025-46-8.m.
32. 122320-73-4.m.
33. 657-24-9.m.
34. OAD.mp.
35. oral hypoglyc?emi$ agent$.mp.
36. oral antidiabet$ agent.mp.
37. *Diabetes Mellitus, Type 2/dt [Drug Therapy]
38. or/1-37
39. exp "Outcome Assessment (Health Care)"/
40. (treatment adj (outcome or failure)).mp.
41. insulin-naive.mp.
42. OHA failure.mp.
43. ((suboptimal$ or poor$ or glyc?emic or diabet$) adj contro?l$).mp.
44. or/39-43
45. Hemoglobin A, Glycosylated/
46. (A1c or A1c).mp.
47. HbA1c.mp.
48. GHb.mp.
49. (hemoglobin or haemoglobin).mp.
50. (glycosylated or glycated).mp.
51. HbA1.mp.
52. or/45-51
53. clinical trial.pt.
54. randomi?ed.ti,ab.
55. placebo.ti,ab.
56. dt.fs.
57. randomly.ti,ab.
58. trial.ti,ab.
59. groups.ti,ab.
60. or/53-59
61. animals/
62. humans/
63. 61 not (61 and 62)
64. 60 not 63
65. gliargine.mp.
66. detemir.mp.
67. ((add-on or "add on") adj3 therap$).mp.
68. Insulin, Isophane/
69. Insulin, Long-Acting/
70. isophane.mp.
71. (long acting or longacting or long-acting).mp.
72. NPH.mp.
73. nph insulin.mp.
74. neutral protamine hagedorn.mp.
75. 53027-39-7.m.
76. or/65-75
77. and/38,44,52,64,76

Please contact authors for details regarding other databases.